 iTeos Therapeutics Inc NASDAQ:ITOS shares are trading higher by 36.7 at 27.38 Monday afternoon after the company and GlaxoSmithKline announced an agreement to co-develop and co-commercialize EOS-448, an anti-TIGIT monoclonal antibody. See Also: iTeos Therapeutics Stock Surges On 2.1B Development Pact For EOS-448 With GSK 